Award Number: DAMD17-01-1-0128

TITLE: Metabolizing Enzyme Polymorphisms and Prognosis Among Women Treated for Breast Cancer

AD

PRINCIPAL INVESTIGATOR: Carol Sweeney, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota Minneapolis, Minnesota 55455-2070

REPORT DATE: October 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# 20030313 151

REPORT DOCUMENTATION PAGE				Form Approved MB No. 074-0188	
Public reporting burden for this collection of inform the data needed, and completing and reviewing thi reducing this burden to Washington Headquarters Management and Budget, Paperwork Reduction P	s collection of information. Send comments reg Services, Directorate for Information Operations	arding this burden estimate or any ot	her aspect of this colle	ction of information, including suggestions for	
1. AGENCY USE ONLY (Leave blank		3. REPORT TYPE AND Annual (28 Sep	<b>D DATES COVERED</b> p 01 - 27 Sep 02)		
4. TITLE AND SUBTITLE Metabolizing Enzyme Polymorphisms and Prognosis Among Women Treated for Breast Cancer			5. FUNDING	NUMBERS	
6.AUTHOR(S) Carol Sweeney, Ph.D.					
	•				
7. PERFORMING ORGANIZATION N	AME(S) AND ADDRESS(ES)		8. PERFORMI	NG ORGANIZATION	
University of Minnesota Minneapolis, Minnesota 55455-2070				JMBER	
$\operatorname{E-Mail:}$ sweeney@epi.umn.edu					
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)			10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
U.S. Army Medical Research and Fort Detrick, Maryland 21702-50			AGENCT		
11. SUPPLEMENTARY NOTES		· · · · · · · · · · · · · · · · · · ·	ـــــــــــــــــــــــــــــــــــــ		
12a. DISTRIBUTION / AVAILABILITY STATEMENT12b. DISTRIBUTION CODEApproved for Public Release; Distribution Unlimited.12b. DISTRIBUTION CODE					
13. ABSTRACT (Maximum 200 Wo	rds)		and a second s		
This study will use ar breast cancer in relat the first year of fund eligible subjects (Tas study start-up tasks, forms, establishing a procedures. Collectio begun. Activities cur review of slides by th reports into the study tasks will continue in at the end of year 1.	ion to inherited polyn ing, we have complete k 1 of the approved s including IRB review, study database, and t n of tissue samples ( rently in progress in e study pathologist, database. As descri	morphisms of drug d compilation of tatement of work hiring study sta raining study sta Task 2 of the app clude obtaining p and abstracting to bed in the states	g metabolis tumor reg ). We have aff, creat aff on data proved sta pathology information ment of wo	zing enzymes. During istry data for e also completed ing data collection a collection tement of work) has slides and blocks, n from pathology rk, data collection	
<b>14. SUBJECT TERMS</b> Breast cancer, GSTP1,	GSTA1 DNA	· · · · · · · · · · · · · · · · · · ·		15. NUMBER OF PAGES 6	
Dicuse cancer, Goiri,	OPINI' NIG	алан Ал	1 - 1 1 - 1	16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSI OF ABSTRACT	FICATION	20. LIMITATION OF ABSTRACT	
Unclassified NSN 7540-01-280-5500	Unclassified	Unclassif		Unlimited	
NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102					

# **Table of Contents**

Cover	1
SF 298	2
Introduction	4
Body	5
Key Research Accomplishments	6
Reportable Outcomes	6
Conclusions	6
References	6
Appendices	6

# INTRODUCTION

Despite the favorable prognosis for women treated for breast cancer, in some instances cancer will recur. Host factors may explain some differences in outcomes of treatment. Variability in enzyme activities could be a factor influencing sensitivity of cells to cancer treatment. Common polymorphisms occur in several genes encoding drug metabolizing enzymes, and the variant alleles affect enzyme activities. Glutathione Stransferase (GST) A1 and GSTP1 enzymes catalyze inactivating glutathionyl conjugation reactions of chemotherapeutics including cyclophosphamide. The GSTA1\*B variant reduces expression of GSTA1, while a GSTP1 Val<sup>105</sup> variant reduces specific activity toward alkylating agents, so these polymorphisms may improve treatment effect by reducing removal of the drug. Data from a pilot study indicate that among women treated for breast cancer, those who are homozygous for GSTP1 Val<sup>105</sup> or GSTA1\*B have improved overall survival. In the present study we will investigate whether presence of inherited variant alleles affecting activity of metabolizing enzymes affect overall survival or time to recurrence outcomes, and whether these associations are independent of other prognostic factors. The study will be a retrospective study of women (n=700) receiving first course of therapy for invasive, primary breast cancer, indentified through a hospital tumor registry. Information on vital status and recurrence will be obtained from registry follow-up data. We will determine genotypes using DNA extracted from normal tissue from archived surgical blocks. We will assess other prognostic markers in tumor tissue by immunohistochemistry. We will use survival analysis methods, taking into account other prognostic factors, to evaluate associations between genotypes and recurrence and overall survival.

4

#### DAMD17-01-1-0128 Annual Report, Oct. 2002

# BODY

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. The Statement of Work identified five tasks, as follows:

Task 1. Compilation of Data for Eligible Subjects, Months 1-3

Task 2. Archived Tissue Specimens Obtained, Months 4-24

Task 3. DNA Extraction and Genotyping, Months 6-30

Task 4. Immunohistochemistry, Months 6-30

Task 5. Data Analysis and Report Writing, Months 18-36

During the first year of funding, we have completed Task 1, compilation of tumor registry data for eligible subjects. We have also completed the following study start-up activities: IRB review and approval; hiring study staff; creating data collection forms for pathology report abstraction and pathological review of each case for eligibility; establishing a database for entering abstracted, unidentified data and tracking specimen status; training study staff on data collection procedures. Task 2, collection of tissue samples, is underway. Activities a. through f. specified under Task 2 are currently in progress including obtaining pathology slides and blocks, review of slides by the study pathologist, and abstracting information from pathology reports into the study database. Samples are being prepared to carry out laboratory assays, Tasks 3 and 4, during years 2 and 3.

# **KEY RESEARCH ACCOMPLISHMENTS**

Data collection activities have been initiated and are proceeding. As described in the Statement of Work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1. The PI presented a poster describing study methods and rationale at the "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 26-28, 2002.

### **REPORTABLE OUTCOMES**

#### Abstract

Sweeney C, Gulbahce HE, Coles BF. Metabolizing enzyme polymorphisms and prognosis among women treated for breast cancer. "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, September 26-28, 2002.

#### **CONCLUSIONS**

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. Data collection activities have been initiated and are proceeding. As described in the Statement of Work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 1.

#### REFERENCES

N/A

#### APPENDICES

N/A